Fig. 5.
Continuous treatment with either haloperidol (0.5mg/kg/day via minipump; CONT-HAL) or olanzapine (10mg/kg/day via minipump; CONT-OLZ) enhanced amphetamine-induced c-fos mRNA expression in the ventrolateral (A: VLO) and lateral (B: LO) orbitofrontal cortices and in the infralimbic (C: IL) and anterior cingulate (D: Cg1 and Cg3) cortices when compared with the CTRL group. n′s = 6–9/condition. α: P < .05 compared with CTRL. Data are means ± SEM. VEH, group injected daily with subcutaneous phosphate-buffered saline; CTRL, combined control group receiving saline; AMPH, amphetamine.
